I D
× COMMENTARYCOVER STORYIN THE NEWSNEWSFRONTSCHEMENTATOR + Show More
Chementator Briefs
Caprolactam Genomatica (San Diego, Calif.; www.genomatica.com) recently announced the production…
BUSINESS NEWSTECHNICAL & PRACTICALFEATURE REPORTFACTS AT YOUR FINGERTIPSTECHNOLOGY PROFILESOLIDS PROCESSINGEQUIPMENT & SERVICESFOCUSNEW PRODUCTS + Show More

Comment Business & Economics

Antibody-drug pair

By Chemical Engineering |

Lonza Group Ltd. (Basel, Switzerland; edlinks.chemengonline.com/6896-549) plans to start large-scale production of antibody drug conjugates (ADCs), an emerging class of products utilized mainly for the treatment of cancer. The plant, located in Visp, Switzerland, will have an initial production capacity of over 100 kg/yr when it comes on line next year. ADCs are made by coupling a highly active chemical substance with a biotechnologically manufactured antibody.
Related Content

Chemical Engineering publishes FREE eletters that bring our original content to our readers in an easily accessible email format about once a week.
Subscribe Now
Improving chemical production processes with IIoT and AI technologies
New filtration technology for highly corrosive media
PTA production: Lowering OPEX without compromising on quality
Sure that zero means zero in your zero-liquid discharge (ZLD) process?
How separation processes profit from Industrial Internet of Things (IIoT) solutions

View More